Recent Updates
Recently added Catalysts

100U EV71 vaccine with adjuvant

Phase 2

Infection, Viral, Enterovirus | Monoclonal antibody | Infectious Disease |Sinovac Biotech, Ltd|Last Updated: Nov 27, 2012

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment540
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01421121Safety and Immunogenicity of an Inactivated EV71 Vaccine in InfantsPHASE2 COMPLETED 540Jun 1, 2011Dec 1, 2011Nov 27, 20121 China
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Neutralization antibody geometric mean titer in infants 28 days after immunization with EV71 vaccine with or without aluminium hydroxide adjuvant
6 month

Primary immunogenicity end point were geometric mean titer of neutralization antibody againt EV71 virus \>= 1:8

Secondary Endpoints
The rates and severity of solicited adverse events in infants following immunization as a Measure of Safety and Tolerability
6 months
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
100U EV71 vaccine with adjuvantEXPERIMENTAL120 infants received 2 doses of 100U EV71 vaccine with aluminium hydroxide adjuvant 28 days apart
200 U EV71 vaccine with adjuvantEXPERIMENTAL120 infants received 2 doses of 200U EV71 vaccine with aluminium hydroxide adjuvant 28 days apart
400U EV71 vaccine with adjuvantEXPERIMENTAL120 infants received 2 doses of 400U EV71 vaccine with aluminium hydroxide adjuvant 28 days apart
200U EV71 vaccine without adjuvantEXPERIMENTAL60 infants received 2 doses of 200U EV71 vaccine without adjuvant 28 days apart
PlaceboPLACEBO_COMPARATOR120 infants received 2 doses of placebo 28 days apart.
Interventions
NameTypeDescription
100U EV71 vaccine with adjuvantBIOLOGICALinactivated vaccine (vero cell) against EV71 of 100U /0.5ml, two doses, 28 days interval
200 U EV71 vaccine with adjuvantBIOLOGICALinactivated vaccine (vero cell) against EV71 of 200U /0.5ml, two doses, 28 days interval
400U EV71 vaccine with adjuvantBIOLOGICALinactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
200U EV71 vaccine without adjuvantBIOLOGICALinactivated vaccine (vero cell) against EV71 without adjuvant of 200U /0.5ml, two doses, 28 days interval
PlaceboBIOLOGICAL0.5ml placebo, two doses, 28 days interval
Unlock Study Design Details
Eligibility Criteria
Age Range6 Months — 35 Months
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Healthy males and females, aged from 6 months to 11 years old Health is determined by medical history, physical examination, laboratory examination and clinical judgment of the investigator 2. Provided legal identification for the sake of recruitment. 3. Subjects and/or paren...

Countries:China
Unlock Eligibility Criteria